← SynDRA
LOSMAPIMOD
SynDRA canonical compound SYN0021680 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | MAPK14 |
|---|
| Mechanism of action | P38 MAPK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MAPK14 INHIBITOR
- MAP kinase p38 alpha inhibitor
- MAPK11 INHIBITOR
- MAP kinase p38 beta inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- MAPKAPK2
- STK24
- SYK
- ACSL5
- PRKACG
- BUB1
- AAK1
- PASK
- PHKG2
- PFKP
- PDXK
- PDGFRB
- PAICS
- PAK4
- PIM2
- OPA1
- OLA1
- NUAK2
- NTRK1
- NQO2
- PIM1
- PIP4K2C
- PIP4K2A
- NEK9
- PRKCD
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PLK1
- PKN3
- PKN2
- PKN1
- PKMYT1
- NLK
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- Gw-856553
- Gw856553
- FTX-1821
- FTX1821
- GSK-AHAB
- GSKAHAB
- GW-856553X
- GW856553X
- GW856553
- UNII-F2DQF16BXE
- F2DQF16BXE
- GW-856553
- 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
- Losmapimod [USAN:INN]
- Losmapimod (GW856553X)
- GW 856553X
- SB 856553
- Losmapimod (USAN/INN)
- SCHEMBL1070401
- GTPL7835
- CHEMBL1088752
- EX-A486
- CHEBI:131167
- KKYABQBFGDZVNQ-UHFFFAOYSA-N
- MolPort-009-194-138
- losmapimod pound>
- HMS3653G19
- BCP09909
- AOB87105
- ZINC35793138
- s7215
- BDBM50418610
- 2523AH
- AKOS015994587
- losmapimodum
- FTX 1821
- RefChem:800053
- DTXCID701401545
Look up LOSMAPIMOD in the interactive SynDRA portal →